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ABSTRACT
Life scientists are often interested to compare two
gene sets to gain insight into differences between
two distinct, but related, phenotypes or conditions.
Several tools have been developed for comparing
gene sets, most of which find Gene Ontology (GO)
terms that are significantly over-represented in
one gene set. However, such tools often return
GO terms that are too generic or too few to be infor-
mative. Here, we present Martini, an easy-to-use
tool for comparing gene sets. Martini is based, not
on GO, but on keywords extracted from Medline
abstracts; Martini also supports a much wider
range of species than comparable tools. To
evaluate Martini we created a benchmark based
on the human cell cycle, and we tested several com-
parable tools (CoPub, FatiGO, Marmite and
ProfCom). Martini had the best benchmark perfor-
mance, delivering a more detailed and accurate
description of function. Martini also gave best or
equal performance with three other datasets
(related to Arabidopsis, melanoma and ovarian
cancer), suggesting that Martini represents an
advance in the automated comparison of gene
sets. In agreement with previous studies, our
results further suggest that literature-derived
keywords are a richer source of gene-function infor-
mation than GO annotations. Martini is freely avail-
able at http://martini.embl.de.
INTRODUCTION
High-throughput experiments such as microarrays, mass
spectrometry, or automated digital microscopy often
produce a single list of genes associated with a speciﬁc
phenotype or condition, and many computational
tools have been developed to help biologists use such
a list to gain insight into the underlying biological pro-
cesses (1). Some of these tools even allow end-users to
interactively explore gene sets, and to identify functional
sub-clusters (2,3).
While a single gene set is probably the most common
outcome of a single experiment, scientists are often
interested to compare two sets deﬁned by two distinct,
but related, phenotypes or conditions. For example, a
scientist may want to compare the set of genes associated
with a primary cancer versus those associated with the
metastatic form of the same cancer (4). Alternatively, a
scientist might want to compare genes associated with a
disease to the genes associated with the presence of a drug.
For this article, we brieﬂy reviewed the available tools
for analyzing gene lists; we found that most tools allow
only a single input gene list, which is usually compared
with the background of all remaining genes in the same
organism. Only a subset of tools allow the user to
explicitly ask the more speciﬁc question: ‘how do two
gene sets diﬀer?’ Clearly, the ability to answer this
question is important and relevant to many life scientists
today.
Of the tools that do address this question [e.g. FatiGO
(5) and ProfCom (6)], most are based on GO (7), a
controlled vocabulary of  30000 terms for describing
gene function. GO-based tools ﬁnd GO terms that are
signiﬁcantly over-represented in one set of genes versus
a second reference set. However, dependency on GO
gives rise to some limitations (8). For many genes, GO
annotations give a very incomplete description of
function, e.g. human genes in Entrez (http://tinyurl
.com/entrez-gene) have a median of only seven GO
terms. As a result, GO-based tools sometimes produce
disappointing results, ﬁnding only a few, or only very
general, GO terms (e.g. see ‘Results’ section).
An alternative approach is to examine the literature
cited in each gene entry, and extract keywords that can
be used to describe gene function. In most cases, the liter-
ature associated with a gene gives a much richer descrip-
tion of function than the currently available GO terms.
For example, human genes in Entrez have a median of
nine Medline (http://pubmed.org) abstracts; clearly, nine
abstracts will contain more information than just seven
GO terms, although the exact number of keywords
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of the keyword dictionary used. Indeed, in at least one
previous study it has been reported that literature-based
approaches give more sensitive and more speciﬁc results
than using only GO terms (9).
Several such keyword-based methods have been
described in the literature (9–14), however, we could
only ﬁnd two systems that are provided as automated,
freely available services, namely CoPub (14) and
Marmite (13). CoPub is based on a dictionary of 250000
keywords, including gene and pathway names, GO
terms, diseases, drugs and tissues. CoPub can only
analyze a single gene set, and it is further restricted to
only human, mouse or rat genes. Marmite is based on
three types of keywords, namely diseases, chemicals and
‘word roots’, or generic ‘bio-terms’. Marmite can compare
two gene sets, but is restricted to human genes only.
In this work we present Martini, a new, easy-to-use tool
that allows end-users to compare two gene sets using a
sensitive, keyword-based method. Martini can be used
with genes from a large number of species, and it uses
a rich keyword dictionary of over 3million terms,
including gene names, drugs, chemicals, diseases,
symptoms, organisms and processes/bio-actions.
MATERIALS AND METHODS
Input data and initial processing
Martini requires the end-user to specify two input sets. By
default Martini assumes the input sets are lists of Entrez
gene IDs (http://tinyurl.com/entrez-gene), in which case
Martini retrieves, for each gene, all PubMed IDs
(http://pubmed.org) that are referred to in the Entrez
entry including the GeneRIFs and interaction records.
The mapping from genes to abstracts is retrieved oﬄine
using SRS (15) and stored in random access memory
(RAM) to enable fast access while processing jobs. Any
gene IDs that occur in both input sets are ignored for the
purpose of subsequent analysis.
Alternatively, the end-user can specify a PubMed query,
in which case Martini queries PubMed via Entrez
Programming Utilities (http://tinyurl.com/eutils-help)
and retrieves a list of PubMed IDs. As a third alternative,
Martini allows the end-user to specify a list of PubMed
IDs directly as input. Thus, for each of the three diﬀerent
types of input to Martini, the initial processing results in a
list of PubMed IDs.
The next step is to convert each PubMed ID into a list
of keywords. For this, we used the AKS2 literature
analysis tool (http://tinyurl.com/bioalma-aks2), which is
based on a keyword dictionary of over 3million entries
covering the following types: drugs, chemicals, genes,
diseases, symptoms, bio-actions and other generic
biologically-relevant keywords. In AKS2, this dictionary
has been used to pre-tag keywords in Medline abstracts,
resulting in an average of 32 keywords per abstract.
In Martini, we extract this information into a hash
table, linking each Medline abstract to a list of AKS2
keywords. By default, Martini uses all keyword types
(genes, drugs, diseases, etc.), however the user can
choose to exclude some types via the ‘Advanced’ option.
Martini relies on the literature that is linked to Entrez
gene entries. In some cases, the Entrez gene entries have
no associated abstracts. In other cases, some Medline
entries contain only titles not abstracts. Another potential
limitation is that AKS2 indexes only the latest 9million
Medline abstracts ignoring older entries. In addition, to
reduce server load and processing time, the total number
of entries in each input ﬁeld of Martini is limited to either
25000 genes or abstracts—if the user speciﬁes more than
this limit, the job will not run, and the user will be asked to
reduce the size of the input sets.
Keyword enhancement
After the initial processing described above, Martini
analyzes each keyword separately to test for statistically-
signiﬁcant over-representation in one input set compared
with the other set, using the two-tailed version of Fisher’s
exact test (16). If the user speciﬁed either a list of PubMed
IDs or a query, Martini counts the numbers of abstracts in
which the keyword occurs at least once. Alternatively, if
the user speciﬁed genes as input, Martini counts the
numbers of genes in which the keyword occurs at least
once in any of the abstracts associated with each gene.
To account for the total number of keywords tested, we
used the false discovery rate method of Benjamini and
Hochberg (17) with a, the fraction of false positives con-
sidered acceptable, set to 5%. The Fisher p-value for each
keyword was then adjusted using:
Adjusted p ¼ min p   n=k,1 ðÞ
where n is the total number of entities in a set, and k is the
rank of the largest p-value that satisﬁes the false discovery
criteria, calculated separately for keywords associated
with each of the two input sets. By default, Martini
returns only those keywords for which the adjusted
p-value is <5%. However, Martini also provides users
access to all keywords found, including those with
higher p-value. The Benjamini and Hochberg method
assumes that all p-values are mutually independent,
which is clearly not true since some words are very likely
to appear together. However the method errs on the con-
servative side, hence we end up rejecting more words than
we should. Ideally we would instead use a permutation-
based approach, as some authors have in similar cases
(18). However, currently this would not be feasible
for Martini as it would require a signiﬁcantly longer
response time.
Comparisons with similar tools
We surveyed the literature for methods that can compare
two gene lists; some of these methods have not been made
available as free tools or services, and others were once
available, but are no longer working. Several of the avail-
able tools have a rather complex user interface; these tools
may have rich functional capabilities, but they do not
provide end-users with a simple way to compare two
gene sets. We found three tools that we considered to be
comparable with Martini, namely FatiGO (5), Marmite
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default parameters, except for FatiGO, where we used
all available database sources (GO terms, pathway
names, etc.). We also tested CoPub (14), which uses a
similarly rich keyword dictionary to Martini, but cannot
compare two genes lists: instead CoPub eﬀectively
compares one list to the background of all genes from
the same organism. However, we included results from
CoPub for one dataset (cell cycle, see below) primarily
to illustrate the beneﬁt of using two datasets. For
CoPub, we again used default parameters and the follow-
ing search categories: ‘biological processes’, ‘Pathway’,
‘Drug’ and ‘Disease’.
In assessing the output of these tools, we attempted
to manually assign each keyword or GO term into one
of three categories: ‘true positive’, ‘false positive’
or ‘uninformative’. The criteria we used for these
assignments are as follows: True positives were deﬁned
as terms that refer to processes or entities that are
unambiguously correct, given the biological context of
the dataset, determined by a manual literature search.
False positives were terms that refer to processes or
entities that are unambiguously incorrect, given the bio-
logical context. Finally, uninformative terms were simply
those that are not clearly right (true positive) and not
clearly wrong (false positive).
Datasets
To compare our work with other tools, we used several
datasets described in this section—these datasets are also
available at http://martini.embl.de.
Arabidopsis. To create a simple test dataset, we used the
Arabidopsis Information Resource, TAIR (19), to ﬁnd
269 Arabidopsis genes that matched the term ‘disease resis-
tance’. We randomly selected a further 514 Arabidopsis
genes that did not match this search term.
Cell cycle. This dataset consisted of 600 periodically
expressed human genes identiﬁed by Jensen et al. (20)
from the original dataset of Whitﬁeld et al. (21). Based
on when in the cell cycle each gene is most highly
expressed, Jensen et al. (20) assigned each gene to
a speciﬁc ‘peak time’, expressed as a percentage of
cell-cycle progress, with 100% (equivalently 0%) corre-
sponding to the moment of cell division. To divide this
dataset into two input sets (A and B), we used a window of
width 10% and slid this window in steps of 1% around the
cell cycle. For example, genes occurring from 1 to 10% of
the cycle were assigned to set A, and the remaining genes
from 11 to 100% were assigned to set B. Next, genes from
2 to 11% were assigned to set A, and so on. In addition,
we partitioned the 600 genes into four subsets correspond-
ing to the classic cell-cycle phases and used these subsets
for a four-state comparison.
Melanoma. This dataset consisted of 290 genes highly
expressed in metastatic melanoma, and 899 genes highly
expressed in primary melanoma based on microarray
analysis (4).
Ovarian cancer. This data set consisted of 160 genes
associated with clear-cell ovarian cancer, and 105 genes
associated with non-clear-cell ovarian cancer, which
includes serous and endometrioid ovarian cancers
grouped together (22).
Cyclic keyword layout
Keywords and GO terms determined using the cell-cycle
dataset were arranged in a circle using a layout algorithm
developed for this work, and written in Mathematica (23).
The algorithm ﬁrst places each word along a circular arc
that spans the exact region of the cell cycle in which the
word is signiﬁcantly over-represented. Next, the algorithm
determines the radius at which to print each word. This is
determined primarily based on the character density, i.e.
number of characters in each keyword divided by the arc
length. Thus, shorter words are placed closer to the center.
Finally, the radial position for some words is modiﬁed
slightly to avoid overlaps with neighboring words.
RESULTS
Arabidopsis dataset
Figure 1 shows the output of a typical keyword analysis
with Martini. In this case, Martini was given two input
sets of genes—the ﬁrst set contained 269 Arabidopsis genes
known to be associated with disease resistance
mechanisms; the second set consisted of 514 genes with
no clear link to disease. Martini found 60 keywords that
were signiﬁcantly over-represented in either of the two
input sets (Figure 1). Manually checking each keyword,
we considered the majority (48 out of 60) to be true
positives, i.e. to be clearly related to disease resistance
mechanisms in plants. For example, Pseudomonas is a
common plant pathogen, and salicylic acid is a
phytohormone that is used by plants in triggering the
defense-signaling pathway.
The 12 keywords that were not true positives were:
access, allele, cause, cognate, cross, enzyme, experiment,
gene product, nucleotide, selected, situation and ursus sp.
We considered that none of these satisﬁed the criteria for
false positives (see ‘Methods’ section), hence we classiﬁed
them as ‘uninformative’. Most of these 12 are too generic
to be properly considered as ‘keywords’, and in future
versions of Martini we plan to automatically blacklist
such uninformative terms.
For comparison, the Arabidopsis datasets were also
analyzed using FatiGO, Marmite and ProfCom, and in
each case exactly zero terms were found.
Table 1 shows the time taken for Martini keyword
enhancement. Generally, the time taken scales better
than linearly with input size, however datasets involving
many well-studied genes will be slower than this estimate.
Cell-cycle dataset
We next tested the keyword enhancement feature of
Martini on a set of 600 human cell-cycle-regulated genes
(20). The human cell cycle is relatively well-studied and
understood, and many of the genes in this data set are
28 Nucleic AcidsResearch, 2010,Vol. 38,No. 1well-characterized (98% are linked to Medline abstracts
describing their function and 86% have GO annotations
levels 3–9 in the GO ontology). Thus, we may expect not
only that methods such as Martini should perform well
with these data, but also that this set may be a good
benchmark, since it should be straightforward to assess
the accuracy of the resulting keywords and GO terms.
Each of these 600 genes has been assigned to a speciﬁc
time point within the cell cycle at which the gene is max-
imally expressed (20). These time points are given as a
percentage of cell-cycle progress rather than hours since
the cycle duration varies between growth conditions. To
construct pairs of gene sets, we used a sliding window
spanning 10% of the cell cycle, and we compared all
genes within the window with the remaining cell-cycle
genes. Sliding the window in 1% steps, we generated 100
Martini keyword analyses spanning the entire cell cycle.
In Figure 2, these results are arranged in a cyclic
layout (see ‘Methods’ section), where each keyword has
been placed to show the exact region of the cell cycle
where the keyword is signiﬁcantly over-represented. The
keywords cluster into three distinct groups: (i) a pre-
replication phase (late G1, corresponding to cell-cycle
progress from 41 to 52% in Figure 2) deﬁned by
keywords that describe the initiation of DNA replication
and the checkpoints that can prevent initiation from
taking place; (ii) S-phase (53–63%), deﬁned by keywords
that describe the proteins, complexes and processes
associated with the replication machinery; (iii) M-phase
(79–100%), which has no keywords for proteins or
complexes, but has keywords that describe the cell
division sub-processes. In G1 and G2 phase (1–40% and
64–78%, respectively) no enhanced keywords are seen,
consistent with the generally-accepted belief that relatively
few processes are speciﬁc to these ‘gap’ phases.
Assessed qualitatively, Figure 2 shows a surprisingly
accurate and precise match to the events and entities
Figure 1. Martini keyword output for the Arabidopsis dataset. All signiﬁcantly enhanced keywords are shown ﬁrst as a ‘keyword cloud’, where the
size of each keyword is proportional to its statistical signiﬁcance. The keywords assigned to input sets A or B are colored blue or black, respectively.
Below the keyword cloud, the signiﬁcant keywords are shown again in a table form, including: the number of times each keyword occurs in each set;
the enhancement factor (i.e. the ratio of the previous numbers); ﬁnally, the table gives an adjusted p-value, which is an estimation of the likelihood
that the given level of keyword enhancement occurred by chance. Note that the total number of genes or abstracts shown in this table may be slightly
less than the number in the user-deﬁned input. This may happen for two reasons: ﬁrst, depending on the user’s choice of genes or abstracts as input,
Martini will remove common items; secondly, some abstracts may not have been indexed in AKS2, and hence they are not counted.
Table 1. Martini performance
Total input Keyword enhancement time
100 abstracts 3s
100 genes 2min
This table can be used to estimate the time required for a Martini
analysis, assuming linear scaling with total input size. For example,
to perform a keyword enhancement using two sets of 500 genes
(=total input of 1000 genes) takes  20min, i.e. 10 times longer than
for 100 genes. The estimates given here are for genes with nine Medline
abstracts (i.e. the median number for human genes). Scaling can be
highly non-linear, e.g. including well-studied genes can take much
longer. However, in practice the actual time taken is often less than
the time estimated from this table.
Nucleic AcidsResearch, 2010,Vol. 38,No. 1 29known to occur at diﬀerent stages of the cell cycle. Of the
72 total keywords found by Martini, we considered 67 to
be ‘true positives’, i.e. to occur at the correct position in
the cell cycle. The remaining ﬁve keywords—‘874 Amino
Acids’, ‘Extractable’, ‘Femtomole’, ‘Tungsten’, ‘20 speciﬁc
protein’—we would classiﬁed as ‘uninformative’ rather
than ‘false positives’, since these keywords do not imply
incorrect processes or entities.
To quantitate the accuracy and precision of the
keywords and terms, we divided the 600 genes into four
groups corresponding to the classic phases G1 (cell cycle
progress from 1 to 40% in Figure 2, giving 113 genes),
S (41–63%, 154 genes), G2 (64–78%, 82 genes) and M
(79–100%, 251 genes). These gene sets were then used to
perform a much simpler four-step analysis, shown in
Table 2, where we compared the genes in each phase
with those in the other three phases (e.g. G1 versus
S+G2+M, etc.). For each of the tools, we then
manually classiﬁed each term found as either true
positive, false positive or uninformative using the follow-
ing criteria: True positives are keywords that have
deﬁnitely been assigned to the correct cell-cycle phase,
i.e. they match to processes or entities known to occur
speciﬁcally within that phase. False positives are
keywords that match to cell-cycle processes, but have
deﬁnitely been assigned to the incorrect phase, e.g.
FatiGO ﬁnds the term ‘M phase’ associated with G1
genes. Since the dataset was deﬁned as genes speciﬁc to
the mitotic cell cycle, we considered any meiosis-speciﬁc
keywords to be false positives. Finally, uninformative
keywords are those that are not clearly right (true
positive) and not clearly wrong (false positive).
CoPub cannot compare two lists, and the results shown
were generated eﬀectively by comparing each of the four
gene subsets against the background of all other human
genes. As expected, CoPub gives less precise results with
more false positives. In fact due to space limitations in
Table 2, we show only ‘biological processes’ from
CoPub; including the other CoPub categories (‘drug’,
‘pathway’, ‘disease’ and ‘liver pathology’) gives nearly
twice as many keywords with a similar pattern of true
and false positives.
Some of the keywords we classiﬁed as uninformative
could arguably be regarded as false positives. For
example, CoPub ﬁnds ‘G2 checkpoint’ and ‘G2/M check-
point’ associated with M-phase genes, however, since
these terms describe a process happening between two
phases, in this simple four-state analysis, we considered
such terms to be neither clearly right or wrong.
Similarly, the Rb:E2F-1:DP-1 transcription factor found
Figure 2. Keywords found by Martini from cell-cycle genes. The ﬁgure shows all keywords found by Martini using 600 cell-cycle-regulated genes
that have been experimentally assigned to speciﬁc time points within the human cell cycle. Percentage numbering indicates cell cycle progress, with
cell division occurring at 100% or 12 o’clock. The arc spanned by each keyword shows the exact region where it is statistically signiﬁcant. The radius
of each keyword is determined by word length. The left-portion of the ﬁgure shows keywords that describe biological processes and functions—these
keywords cluster into three distinct phases: M-, S- and a pre-replication phase. The right-portion of the ﬁgure is a close-up of the pre-replication and
S-phase regions showing keywords that specify genes, proteins or complexes. The keywords shown, and their positions show a surprisingly accurate
and precise match to the sub-phases, processes, and entities known to occur in the cell cycle (see also Table 3).
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l
l
d
i
ﬀ
e
r
e
n
t
i
a
t
i
o
n
;
G
e
n
e
s
i
l
e
n
c
i
n
g
;
G
r
o
w
t
h
p
a
t
t
e
r
n
;
H
i
s
t
o
g
e
n
e
s
i
s
;
I
n
t
r
a
c
e
l
l
u
l
a
r
t
r
a
n
s
p
o
r
t
;
K
e
r
a
t
i
n
o
c
y
t
e
d
i
ﬀ
e
r
e
n
t
i
a
t
i
o
n
;
M
o
r
p
h
o
g
e
n
e
s
i
s
;
m
R
N
A
s
t
a
b
i
l
i
z
a
t
i
o
n
;
N
u
c
l
e
o
c
y
t
o
p
l
a
s
m
i
c
t
r
a
n
s
p
o
r
t
;
O
n
c
o
g
e
n
e
s
i
s
;
O
r
g
a
n
o
g
e
n
e
s
i
s
;
P
h
o
s
p
h
o
r
y
l
a
t
i
o
n
;
P
r
o
t
e
i
n
f
o
l
d
i
n
g
,
i
m
p
o
r
t
;
R
e
s
p
o
n
s
e
t
o
h
y
p
o
x
i
a
;
R
N
A
i
n
t
e
r
f
e
r
e
n
c
e
;
R
N
A
p
r
o
c
e
s
s
i
n
g
;
S
e
n
e
s
c
e
n
c
e
;
S
i
g
n
a
l
t
r
a
n
s
d
u
c
t
i
o
n
;
S
y
n
a
p
t
o
n
e
m
a
l
c
o
m
p
l
e
x
f
o
r
m
a
t
i
o
n
,
s
y
n
a
p
t
o
g
e
n
e
s
i
s
;
T
r
a
n
s
c
r
i
p
t
i
o
n
;
T
r
a
n
s
d
u
c
t
i
o
n
;
T
r
a
n
s
l
a
t
i
o
n
.
T
r
u
e
p
o
s
i
t
i
v
e
:
B
a
s
e
-
e
x
c
i
s
i
o
n
r
e
p
a
i
r
5
;
C
h
r
o
m
a
t
i
n
s
i
l
e
n
c
i
n
g
3
,
r
e
m
o
d
e
l
i
n
g
,
m
o
d
i
ﬁ
c
a
t
i
o
n
,
i
n
s
u
l
a
t
o
r
s
e
q
u
e
n
c
e
b
i
n
d
i
n
g
;
D
N
A
d
a
m
a
g
e
r
e
s
p
o
n
s
e
5
,
m
e
t
a
b
o
l
i
s
m
2
,
m
e
t
h
y
l
a
t
i
o
n
4
,
r
e
c
o
m
b
i
n
a
t
i
o
n
4
,
r
e
p
a
i
r
5
,
r
e
p
l
i
c
a
t
i
o
n
4
,
s
y
n
t
h
e
s
i
s
2
,
u
n
w
i
n
d
i
n
g
5
;
D
o
u
b
l
e
-
s
t
r
a
n
d
b
r
e
a
k
r
e
p
a
i
r
5
;
H
y
p
e
r
p
h
o
s
p
h
o
r
y
l
a
t
i
o
n
3
;
M
i
s
m
a
t
c
h
r
e
p
a
i
r
5
;
N
u
c
l
e
o
t
i
d
e
-
e
x
c
i
s
i
o
n
r
e
p
a
i
r
5
;
P
o
s
t
r
e
p
l
i
c
a
t
i
o
n
r
e
p
a
i
r
5
;
R
e
c
o
m
b
i
n
a
t
i
o
n
4
;
R
e
c
o
m
b
i
n
a
t
i
o
n
a
l
r
e
p
a
i
r
5
;
S
i
n
g
l
e
-
s
t
r
a
n
d
e
d
D
N
A
b
i
n
d
i
n
g
8
;
S
t
r
a
n
d
d
i
s
p
l
a
c
e
m
e
n
t
8
;
T
e
l
o
m
e
r
e
m
a
i
n
t
e
n
a
n
c
e
5
.
F
a
l
s
e
p
o
s
i
t
i
v
e
:
D
i
v
i
s
i
o
n
1
1
;
M
p
h
a
s
e
1
1
;
M
i
t
o
s
i
s
1
1
;
M
e
i
o
s
i
s
c
h
r
o
m
o
s
o
m
e
s
e
g
r
e
g
a
t
i
o
n
,
m
e
i
o
s
i
s
;
M
e
i
o
s
i
s
s
i
s
t
e
r
c
h
r
o
m
a
t
i
d
c
o
h
e
s
i
o
n
,
m
e
i
o
s
i
s
I
I
;
M
e
i
o
t
i
c
r
e
c
o
m
b
i
n
a
t
i
o
n
;
M
e
t
a
p
h
a
s
e
1
4
.
U
n
i
n
f
o
r
m
a
t
i
v
e
:
A
p
o
p
t
o
s
i
s
;
A
T
P
t
r
a
n
s
p
o
r
t
,
r
e
g
e
n
e
r
a
t
i
o
n
,
m
e
t
a
b
o
l
i
s
m
,
h
y
d
r
o
l
y
s
i
s
,
c
a
t
a
b
o
l
i
s
m
,
b
i
o
s
y
n
t
h
e
s
i
s
;
B
u
d
d
i
n
g
;
C
e
l
l
c
y
c
l
e
,
a
r
r
e
s
t
,
c
h
e
c
k
p
o
i
n
t
;
C
e
l
l
d
e
a
t
h
,
g
r
o
w
t
h
a
n
d
/
o
r
m
a
i
n
t
e
n
a
n
c
e
,
c
e
l
l
g
r
o
w
t
h
,
p
r
o
l
i
f
e
r
a
-
t
i
o
n
;
D
N
A
a
m
p
l
i
ﬁ
c
a
t
i
o
n
,
f
r
a
g
m
e
n
t
a
t
i
o
n
;
D
r
u
g
r
e
s
i
s
t
a
n
c
e
;
G
e
n
e
c
o
n
v
e
r
s
i
o
n
,
e
x
p
r
e
s
-
s
i
o
n
A
N
D
e
p
i
g
e
n
e
t
i
c
,
s
i
l
e
n
c
i
n
g
;
H
i
s
t
o
n
e
a
c
e
t
y
l
a
t
i
o
n
;
I
n
d
u
c
t
i
o
n
o
f
a
p
o
p
t
o
s
i
s
;
M
a
t
i
n
g
b
e
h
a
v
i
o
r
,
m
a
t
i
n
g
;
m
R
N
A
s
p
l
i
c
i
n
g
,
s
p
l
i
c
e
s
i
t
e
s
e
l
e
c
t
i
o
n
;
M
u
t
a
g
e
n
e
s
i
s
;
O
n
c
o
g
e
n
e
s
i
s
;
P
h
o
s
p
h
o
r
y
l
a
t
i
o
n
;
R
b
:
E
2
F
-
1
:
D
P
-
1
t
r
a
n
s
c
r
i
p
-
t
i
o
n
f
a
c
t
o
r
;
R
N
A
i
n
t
e
r
f
e
r
e
n
c
e
;
S
e
n
e
s
c
e
n
c
e
;
T
r
a
n
s
c
r
i
p
t
i
o
n
,
m
i
t
o
t
i
c
,
i
n
i
t
i
a
t
i
o
n
;
T
r
a
n
s
l
a
t
i
o
n
;
V
i
r
a
l
r
e
p
l
i
c
a
t
i
o
n
.
F
a
l
s
e
P
o
s
i
t
i
v
e
:
A
n
a
p
h
a
s
e
A
a
n
d
B
1
5
;
C
h
r
o
m
a
t
i
n
s
i
l
e
n
c
i
n
g
3
,
r
e
m
o
d
e
l
i
n
g
,
m
o
d
i
ﬁ
c
a
t
i
o
n
,
i
n
s
u
l
a
t
o
r
s
e
q
u
e
n
c
e
b
i
n
d
i
n
g
;
C
h
r
o
m
o
s
o
m
e
c
o
n
d
e
n
s
a
t
i
o
n
1
3
,
s
e
g
r
e
g
a
t
i
o
n
1
5
,
m
o
v
e
m
e
n
t
;
D
i
v
i
s
i
o
n
1
1
;
D
N
A
d
a
m
a
g
e
r
e
s
p
o
n
s
e
1
5
,
m
e
t
h
y
l
a
t
i
o
n
4
,
r
e
p
a
i
r
5
,
r
e
p
l
i
c
a
-
t
i
o
n
4
,
s
y
n
t
h
e
s
i
s
2
;
M
p
h
a
s
e
1
1
;
M
e
i
o
s
i
s
s
i
s
t
e
r
c
h
r
o
m
a
t
i
d
c
o
h
e
s
i
o
n
,
I
I
s
p
i
n
d
l
e
a
s
s
e
m
b
l
y
,
I
s
p
i
n
d
l
e
a
s
s
e
m
b
l
y
,
c
h
r
o
m
o
s
o
m
e
s
e
g
r
e
g
a
t
i
o
n
;
M
e
t
a
p
h
a
s
e
1
4
;
M
i
s
m
a
t
c
h
r
e
p
a
i
r
5
;
M
i
t
o
s
i
s
1
1
;
N
u
c
l
e
o
t
i
d
e
-
e
x
c
i
s
i
o
n
r
e
p
a
i
r
5
;
P
a
c
h
y
t
e
n
e
;
P
r
o
p
h
a
s
e
1
2
;
R
e
c
o
m
b
i
n
a
t
i
o
n
4
;
S
p
e
r
m
a
t
o
g
e
n
e
s
i
s
.
U
n
i
n
f
o
r
m
a
t
i
v
e
:
A
n
t
i
g
e
n
p
r
e
s
e
n
t
a
t
i
o
n
;
A
p
o
p
t
o
s
i
s
;
A
u
t
o
p
h
o
s
p
h
o
r
y
l
a
t
i
o
n
;
B
u
d
d
i
n
g
;
C
a
s
p
a
s
e
a
c
t
i
v
a
t
i
o
n
;
C
e
l
l
c
y
c
l
e
,
a
r
r
e
s
t
,
c
h
e
c
k
p
o
i
n
t
,
d
e
a
t
h
,
i
n
v
a
s
i
o
n
;
C
h
e
m
o
t
a
x
i
s
;
C
o
n
j
u
g
a
t
i
o
n
;
D
N
A
f
r
a
g
m
e
n
t
a
t
i
o
n
;
D
e
p
h
o
s
p
h
o
r
y
l
a
t
i
o
n
;
F
r
a
g
m
e
n
t
a
t
i
o
n
;
G
e
n
e
s
i
l
e
n
c
i
n
g
;
G
l
u
t
a
t
h
i
o
n
e
m
e
t
a
b
o
l
i
s
m
,
c
o
n
j
u
g
a
-
t
i
o
n
r
e
a
c
t
i
o
n
,
c
a
t
a
b
o
l
i
s
m
,
b
i
o
s
y
n
t
h
e
s
i
s
;
H
i
s
t
o
n
e
a
c
e
t
y
l
a
t
i
o
n
;
I
n
d
u
c
t
i
o
n
o
f
a
p
o
p
t
o
s
i
s
;
I
n
ﬂ
a
m
m
a
t
o
r
y
r
e
s
p
o
n
s
e
;
m
R
N
A
t
r
a
n
s
c
r
i
p
t
i
o
n
;
R
N
A
i
n
t
e
r
f
e
r
e
n
c
e
;
T
r
a
n
s
c
r
i
p
t
i
o
n
,
i
n
i
t
i
a
t
i
o
n
.
T
r
u
e
p
o
s
i
t
i
v
e
:
A
b
s
c
i
s
s
i
o
n
1
6
;
A
n
a
p
h
a
s
e
A
a
n
d
B
1
5
;
C
e
l
l
d
i
v
i
s
i
o
n
1
1
;
C
e
n
t
r
o
s
o
m
e
s
e
p
a
r
a
t
i
o
n
1
5
,
c
y
c
l
e
;
C
h
r
o
m
o
s
o
m
e
c
o
n
d
e
n
s
a
t
i
o
n
1
3
,
s
e
g
r
e
g
a
t
i
o
n
1
5
,
m
o
v
e
m
e
n
t
1
3
–
1
5
;
C
y
t
o
k
i
n
e
s
i
s
1
1
;
D
i
v
i
s
i
o
n
1
1
;
E
n
v
e
l
o
p
e
b
r
e
a
k
d
o
w
n
1
2
;
E
x
i
t
f
r
o
m
m
i
t
o
s
i
s
1
4
;
M
p
h
a
s
e
1
1
;
M
e
t
a
p
h
a
s
e
1
4
;
M
e
t
a
p
h
a
s
e
–
a
n
a
p
h
a
s
e
t
r
a
n
s
i
t
i
o
n
1
4
;
M
i
c
r
o
t
u
b
u
l
e
1
8
p
r
o
c
e
s
s
e
s
;
M
i
t
o
s
i
s
1
1
;
P
r
o
m
e
t
a
p
h
a
s
e
1
3
;
P
r
o
p
h
a
s
e
1
2
;
S
i
s
t
e
r
c
h
r
o
m
a
t
i
d
c
o
h
e
s
i
o
n
a
n
d
s
e
p
a
r
a
t
i
o
n
1
5
;
S
p
i
n
d
l
e
e
l
o
n
g
a
t
i
o
n
1
3
,
a
s
s
e
m
b
l
y
1
3
,
s
t
a
b
i
l
i
z
a
t
i
o
n
1
4
,
c
h
e
c
k
p
o
i
n
t
1
4
;
T
e
l
o
p
h
a
s
e
1
6
.
F
a
l
s
e
p
o
s
i
t
i
v
e
:
D
N
A
r
e
p
l
i
c
a
t
i
o
n
a
n
d
s
y
n
t
h
e
s
i
s
4
;
E
m
b
r
y
o
n
i
c
d
e
v
e
l
o
p
m
e
n
t
;
F
e
r
t
i
l
i
z
a
t
i
o
n
;
M
e
i
o
s
i
s
s
i
s
t
e
r
c
h
r
o
m
a
t
i
d
c
o
h
e
s
i
o
n
,
I
I
s
p
i
n
d
l
e
a
s
s
e
m
b
l
y
,
I
s
p
i
n
d
l
e
a
s
s
e
m
b
l
y
,
c
h
r
o
-
m
o
s
o
m
e
s
e
g
r
e
g
a
t
i
o
n
;
O
o
c
y
t
e
m
a
t
u
r
a
t
i
o
n
;
O
o
g
e
n
e
s
i
s
;
O
s
t
e
o
b
l
a
s
t
d
i
ﬀ
e
r
e
n
t
i
a
t
i
o
n
;
P
a
c
h
y
t
e
n
e
;
S
p
e
r
m
a
t
o
g
e
n
e
s
i
s
;
s
s
D
N
A
b
i
n
d
i
n
g
8
.
U
n
i
n
f
o
r
m
a
t
i
v
e
:
A
d
i
p
o
c
y
t
e
d
i
ﬀ
e
r
e
n
t
i
a
t
i
o
n
;
A
n
g
i
o
g
e
n
e
s
i
s
;
A
n
t
i
-
a
p
o
p
t
o
s
i
s
;
A
n
t
i
v
i
r
a
l
r
e
s
p
o
n
s
e
;
A
p
o
p
t
o
s
i
s
;
A
u
t
o
p
h
o
s
p
h
o
r
y
l
a
t
i
o
n
;
B
u
d
d
i
n
g
;
C
a
s
p
a
s
e
a
c
t
i
v
a
t
i
o
n
;
C
e
l
l
a
d
h
e
s
i
o
n
,
c
y
c
l
e
a
r
r
e
s
t
,
c
y
c
l
e
c
h
e
c
k
p
o
i
n
t
,
d
e
a
t
h
,
d
i
ﬀ
e
r
e
n
-
t
i
a
t
i
o
n
,
f
a
t
e
s
p
e
c
i
ﬁ
c
a
t
i
o
n
,
f
a
t
e
d
e
t
e
r
m
i
n
a
t
i
o
n
,
f
a
t
e
c
o
m
-
m
i
t
m
e
n
t
,
g
r
o
w
t
h
a
n
d
-
o
r
m
a
i
n
t
e
n
a
n
c
e
,
g
r
o
w
t
h
,
i
n
v
a
s
i
o
n
,
m
i
g
r
a
t
i
o
n
,
m
o
t
i
l
i
t
y
,
p
o
l
a
r
i
t
y
,
p
r
o
l
i
f
e
r
a
t
i
o
n
,
s
i
z
e
;
C
e
l
l
–
c
e
l
l
a
d
h
e
s
i
o
n
;
C
y
t
o
s
k
e
l
e
t
o
n
;
D
e
p
h
o
s
p
h
o
r
y
l
a
t
i
o
n
;
D
N
A
d
a
m
a
g
e
r
e
s
p
o
n
s
e
,
f
r
a
g
m
e
n
t
a
t
i
o
n
,
r
e
p
a
i
r
;
D
o
u
b
l
e
-
s
t
r
a
n
d
b
r
e
a
k
r
e
p
a
i
r
;
E
p
i
t
h
e
l
i
a
l
c
e
l
l
p
r
o
l
i
f
e
r
a
t
i
o
n
,
d
i
ﬀ
e
r
e
n
t
i
a
t
i
o
n
;
F
i
b
r
o
b
l
a
s
t
p
r
o
l
i
f
e
r
a
t
i
o
n
;
F
r
a
g
m
e
n
t
a
t
i
o
n
;
G
-
p
r
o
t
e
i
n
s
i
g
n
a
l
i
n
g
;
G
2
c
h
e
c
k
p
o
i
n
t
;
G
2
/
M
c
h
e
c
k
p
o
i
n
t
,
t
r
a
n
s
i
t
i
o
n
;
G
a
s
t
r
u
l
a
t
i
o
n
;
G
e
n
e
e
x
p
r
e
s
s
i
o
n
,
e
p
i
g
e
n
e
t
i
c
,
s
i
l
e
n
c
i
n
g
;
G
r
o
w
t
h
;
H
i
s
t
o
n
e
a
c
e
t
y
l
a
t
i
o
n
,
m
o
d
i
ﬁ
c
a
t
i
o
n
;
H
y
p
e
r
p
h
o
s
p
h
o
r
y
l
a
t
i
o
n
;
I
n
d
u
c
t
i
o
n
o
f
a
p
o
p
t
o
s
i
s
;
L
u
n
g
d
e
v
e
l
o
p
m
e
n
t
;
M
a
m
m
a
r
y
g
l
a
n
d
d
e
v
e
l
o
p
m
e
n
t
;
M
e
v
a
l
o
n
a
t
e
t
r
a
n
s
p
o
r
t
,
p
a
t
h
w
a
y
;
M
i
g
r
a
t
i
o
n
;
(
c
o
n
t
i
n
u
e
d
)
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C
o
n
t
i
n
u
e
d
T
o
o
l
G
1
S
G
2
M
M
o
r
p
h
o
g
e
n
e
s
i
s
;
m
R
N
A
p
r
o
c
e
s
s
i
n
g
,
s
p
l
i
c
i
n
g
,
s
p
l
i
c
e
s
i
t
e
s
e
l
e
c
t
i
o
n
,
t
r
a
n
s
p
o
r
t
;
M
y
o
g
e
n
e
s
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Terms such as ‘cell cycle’, ‘cell cycle checkpoint’ and
‘hydrolase’ are not incorrect, but since they refer to pro-
cesses throughout the entire cycle, it is also not correct
to assign them to a single cell-cycle phase. Another bor-
derline case is ‘DNA damage’, which is a key feature of
S-phase, but is also present in other phases, hence we
regarded it as a true positive if it occurs in S-phase, but
as uninformative for other phases. CoPub also ﬁnds terms
such as ‘lung development’ that appear to be incorrect,
given how the gene set was deﬁned, however since this
term does not clearly match to any speciﬁc cell-cycle
process, we categorized it as ‘uninformative’.
To calculate a recall score, we created a benchmark
or ‘score card’ that deﬁnes 20 main phases, sub-processes
and key components in the human cell cycle (Table 3).
Each true positive in Table 2 was then mapped onto one
row of Table 3, allowing us to count non-redundant true
positives (tp), and also to count false negatives (fn,
i.e. rows in Table 3 for which a tool has no matching
keywords). The recall was then calculated as tp/
(tp+fn), and the precision calculated as tp/(tp+fp),
where fp stands for the number of false positives in
Table 3. Note that the number of false positives has no
clear limit, hence the precision score used here is an
estimate of the ‘true’ precision.
Of the ﬁve tools tested against this benchmark, Martini
clearly gave the best performance, with 60% recall
and 100% precision. CoPub found many more keywords
and had similarly good recall (60%), but only 17%
precision (i.e. many false positives). FatiGO also found
more keywords than Martini, but had lower recall
(25%) and lower precision (45%). Marmite found zero
terms in all of the phases, while ProfCom found only
the single term ‘hydrolase activity’ that we judged to be
uninformative.
Melanoma dataset
We next tested keyword enhancement using two gene sets,
one associated with primary melanoma and another with
metastatic melanoma (4). In contrast to the very speciﬁc
comparisons of cell-cycle phases in Table 2, comparing
these two types of melanoma corresponds to asking
a more general question. We considered the melanoma
dataset to be not a good candidate as a benchmark,
unlike the cell-cycle dataset, but probably a more realistic
or typical case.
Table 4 compares the output of FatiGO, Marmite,
Martini and ProfCom with these data. We manually clas-
siﬁed each keyword found as either mitosis-related,
uninformative, or ‘not mitosis-related’ using the following
criteria (diﬀerent to the cell-cycle criteria). Mitosis-related
keywords have a clear relation to the major mitosis-
speciﬁc processes. Since mitotic cell division is what we
would expect to see associated with metastatic cancer,
we considered these keywords to be true positives.
Uninformative keywords were either too generic (e.g.
‘assemblies’ or ‘biogenesis’), or related to experimen-
tal techniques (e.g. ‘co-immunoprecipitation’), or related
to model organisms (‘cerevisiae’ or ‘sporulation’).
Any remaining keywords were classiﬁed as Not mitosis-
related. Keywords in this ﬁnal category are the most inter-
esting as their connection to melanoma and metastasis is,
in many cases, not immediately obvious. In contrast to
Arabidopsis and the human cell-cycle, where many of us
have extensive experience, we had little previous experi-
ence with the melanoma literature, and hence we were less
conﬁdent in deciding true and false positives.
Martini found 264 signiﬁcantly-enhanced keywords,
a much larger number than the other methods (Table
4). Of the keywords found by Martini, 109 were mitosis-
related and 79 were uninformative. This left 76 keywords
assigned as ‘not mitosis-related’; for each of these we
manually checked the literature for evidence of a connec-
tion to melanoma or metastasis. For some keywords,
this connection was straightforward, e.g. skin, cornea,
lymphoid, HeLa cells, desmosome, intermediate ﬁlaments,
involucrin, calcium, as well as several skin diseases.
For other keywords, the connection was less obvious,
but was supported by the literature: e.g. polyploidy (24),
corniﬁcation and bone marrow cells (25), heat-shock/
chaperone proteins (26), cystic ﬁbrosis (27), ATM
kinases (28), CHK1 (29), neurites (30). Perhaps the most
interesting keywords found by Martini are the names of
several of the MAGE (melanoma-associated genes) gene
family. These genes are normally expressed only in
developing sperm, where they play a role in meiotic cell
division. However, these genes are also expressed in
melanoma (31,32).
FatiGO found 4 transcription factors and 47 GO terms,
of which 36 were classiﬁed as not mitosis-related (Table 4).
As with Martini, all the terms in the ‘not mitosis-related’
category seemed to have a general connection to
melanoma or metastasis, hence none were obviously
false positives. Interestingly, FatiGO does not ﬁnd the
link to spermatogensis.
Comparing Martini and FatiGO qualitatively, both
seemed to have similar precision with this dataset, i.e.
all terms and keywords found were either uninformative
or, as best as we could judge true positives, correctly
indicating a connection to melanoma or metastasis.
Martini found many more keywords, more-speciﬁc
keywords and also more uninformative keywords.
Martini also found many processes related to melanoma
and metastasis that were not found by FatiGO. Thus, we
conclude that Martini had qualitatively a somewhat
higher recall, however, unlike the human cell cycle, we
cannot quantify this since we do not have the background
to construct a benchmark covering all the major processes
and components involved. Marmite and ProfCom did
not perform well with this dataset, ﬁnding almost no
terms (Table 4).
Ovarian cancer dataset
As a ﬁnal test of keyword enhancement, we used FatiGO,
Marmite, Martini and ProfCom to compare a set of 160
genes associated with clear-cell ovarian cancer (i.e. cells
that are clear when viewed through a microscope), and a
second set of 105 genes associated with non-clear-cell
ovarian cancer. For this comparison, each of the tools
Nucleic AcidsResearch, 2010,Vol. 38,No. 1 33found exactly zero signiﬁcantly enhanced keywords or GO
terms.
DISCUSSION
Which tool best predicts function?
In this work we have compared Martini with several
other tools with similar functionality, and overall
Martini performs favorably for the speciﬁc cases we
tested. However, comparing such tools is complex and
multifaceted. Many criteria need to be considered
making it diﬃcult to judge which tool is the ‘best’, for
example, some end-users may prefer tools that oﬀer
advanced features and functionality, even though
these tools may take longer to learn. Martini oﬀers
fewer advanced features than many other tools, since we
designed it for end-users who require a simple, easy-to-use
Table 3. Cell-cycle benchmark and score-card
Cell-cycle phases, processes and components Martini Marmite CoPub FatiGO ProfCom
Synonyms/related genes
1. G1-Phase Gap 1
2. S-Phase DNA metabolism, synthesis; synthesis phase 1 1
Sub-processes: 1
(i) Replication initiation Chromatin silencing; Hyperphosphorylation
(ii) DNA replication DNA methylation, synthesis, recombination 1 1 1
(iii) DNA repair Base-excision repair; DNA damage response, unwind-
ing; double-strand break repair; mismatch repair;
nucleotide-excision repair; post-replication repair;
Telomere maintenance
11
Key components:
(i) Origin of replication
complex
Claspin; ORC
(ii) Mini-chromosome
maintenance complex
MCM2-7
(iii) Replication fork CHL12; DNA ligase; DNA polymerase; DNA
replication factor; Helicase; holoenzyme; lagging
strand; leading strand; Okazaki fragments; PCNA;
PCNA-binding protein; pre-replication complex;
primase; processivity; replication protein A (RP-A);
replication factor C (RFC); single-stranded DNA;
ssDNA-binding proteins; Strand displacement;
Topoisomerase.
11
3. DNA repair proteins Ataxia Telangiectasia mutated gene (ATM), ATR,
ATR-interacting proteins; ATRIP; CHK1 kinase,
CHK2 kinase; HUS1
1
4. G2-Phase Gap 2
5. M-Phase Cell division; ‘Karyokinesis and cytokinesis’; Mitosis;
Mitotic division; ‘Not interphase’
11 1
Sub-processes: 11
(i) Prophase Envelope breakdown.
(ii) Prometaphase Chromosome condensation; spindle assembly; spindle
elongation
11
(iii) Metaphase BubR1; chromosome alignment; hyperphosphorylation;
metaphase–anaphase transition; mitotic checkpoint;
mitotic exit checkpoint; mitotic spindle checkpoint;
spindle stabilization
11
(iv) Anaphase APC/C; centrosome separation; chromatid separation;
chromosome segregation; sister chromatid separation
11
(v) Telophase Multinuclear 1 1
(vi) Cytokinesis Abscission 1
Key components: 11 1
(i) Mitotic spindle Aster; centrosomes; centriole pair; Kinetochore;
microtubules; mitotic center
(ii) Metaphase plate Midzone 1
(iii) Cleavage furrow Contractile ring; non-muscle myosin II+actin ﬁlaments
True Positives
(non-redundant)
12 0 12 5 0
False Negatives 8 20 8 15 20
False Positives 00 5 86 0
Recall 60% 0% 60% 25% 0%
Precision 100% – 17% 46% –
This table lists 20 key features of the human cell cycle, and uses this feature list as a benchmark to compare the performance of diﬀerent tools
based on their output (Table 2).
34 Nucleic AcidsResearch, 2010,Vol. 38,No. 1tool that gives quick insight into the functional diﬀerences
between two gene lists.
Another important criterion is the range of organisms
that a tool can be applied to. Most of the tools we could
ﬁnd that are comparable to Martini (e.g. FatiGO,
Marmite and ProfCom) can work only with genes from
human plus a small number of model organisms. Martini
has a much greater range, since it can be used with any
organism in the Entrez gene database. Furthermore,
Martini even allows comparison of genes across diﬀerent
organisms, whereas almost all similar tools usually restrict
comparisons to genes within the same organism.
Finally, accuracy is clearly a very important criterion
for assessing tools such as Martini. Unfortunately,
accuracy can be diﬃcult to assess objectively and to
quantify reliably. What is required is a set of reliable
benchmarks tailored speciﬁcally for comparing two gene
sets, ideally spanning a wide range of functions and
organisms. In this article, we have taken a step in this
direction by proposing one such benchmark (Table 3)
that can be used with gene sets related to the human cell
cycle (see ‘Results’ section). Since the human cell cycle is
very well-studied, this benchmark probably represents a
‘best-case’, and the performance of such tools is likely to
be worse for most other datasets (e.g. for the ovarian-
cancer dataset, none of tools tested could ﬁnd any
keywords or GO terms). We designed this benchmark to
cover only the 20 most important phases, sub-processes
and components in the cell cycle; however, as tools
improve it would eventually be useful to create a more
Table 4. Keywords for metastatic versus primary melanoma
Tool Keywords/GO terms
Martini Mitosis-related: Anaphase; APC/C; Arrest; Ataxia telangiectasia; BUBR1; Camptothecin; CDC20; CDH1; CDK2; CDK2 kinase;
CDT1; Cell cycle; Cell division; Centrosome; Checkpoint; Chromatid; Claspin; Cohesin; Cyclin B; Cyclin-dependent; Cyclin-
dependent kinases; Cyclosome; Cytogenetic; Cytokinesis; DNA damage; DNA repair; DNA replication; DNA-binding protein;
Double-strand break; Double-stranded DNA; E2F transcription factor; E2F4; EGF; Elongation; Elongation factor; Fork; G2-phase;
Guanine nucleotide; H2B; Helicase, Initiation factor; High-sensitive reverse transcription-nested polymerase chain; Histone;
Histones; Intermediate ﬁlament; Interphase; Junctional; Kinase; Kinases; Kinetics; Kinetochore; Ligases; Ligated; M-phase; MAD1;
MAD2; Metaphase; Microtubule; Midbodies; Midzone; Minichromosome; Misalignment; Missegregation; Mitotic; Mitotic spindle;
Monopolar; Multipolar; Non-phosphorylatable; Nuclear antigen; Nuclear pore; Nuclear protein; Nucleolar; Nucleus;
Oligoribonucleotides; PCNA; Phosphopeptides; Phosphoprotein; Phosphoproteins; Phosphorylation; Pol; Polo-like kinase 1;
Polypeptide chain elongation factor 1 alpha; Posttranslational; Prometaphase; Prophase; Proteasome; Protein kinase; RAD17;
rDNA; Replication; Replication protein A; Ribonucleotide; Ribosomal gene; Ribosome; Ring-shaped; RNA polymerase; RNA
polymerase I subunit; RP-A; S-phase; Segregation; Small nuclear ribonucleoprotein; Small nuclear ribonucleoprotein particle; spindle
associated proteins; ssDNA; Telophase; Topoisomerase; Topoisomerase I; Ubiquitin; ubiquitin ligases; Ubiquitins
Uninformative: Assembled; Assemblies; Binaries; Biogenesis; Cerevisiae; Clade; Classiﬁcation; Co-immunoprecipitation; Connection;
Coordination; Cross-validation; Daughter; Degradation; Depletion; Dispensable; Dynamics; Empirical; End; Essential; Eukaryote;
Eukaryotic; Eukaryotic cell; False-positive; Fraction; Global; Health; Hit; Human protein-protein; Immunodepleted; Imprinting;
In-gel; Independent; Integrated; Invaluable; Lates; Layer; Leaves; Linings; Liquid chromatography-tandem mass spectrometry;
Lysate; Machine; Mappings; Mass spectrometries; Matched; Mechanism; Microinjection; Motif; Motor; Multisubunit; Mus sp;
Nascent; Nationals; Network; Nicotiana tabacum; Non-redundant; Oligoribonucleotide; Pairwise; Percent; Permit; Puriﬁed; Remain;
Removed; Saccharomyces cerevisiae; Scale; Schizosaccharomyces; Schizosaccharomyces pombe; Spectral; Stable isotope; Stem-loop;
Step; Stringent; Supplemental; Surprisingly; Systematics; Tobacco; Unlike; Unprecedented; Unsolved; Upper
Not mitosis-related: 12 MAGE; 50-phosphates; 941 pseudogenes; ATPase; aneuploidy; ATM kinases; Autism; Bone marrow cell;
Bronchial; Calcium; Calcium-dependent; Chaperone; CHK1 protein kinase; Cornea; Corniﬁed; Cystic ﬁbrosis gene; Desmosome;
Epidermal cell; Epithelial; Epithelial cell; Epithelium; Human gene MAGE-1; Guanine nucleotide exchange factors; Heat-shock;
HSPs; Hair follicle; HeLa cell; HeLa cell nuclear; Involucrin; Keratinocyte; Lymphoid-speciﬁc; MAGE; MAGE-A; MAGE-A
antigens; Melanoma antigen gene; Neurite; Novel protein-protein; Over 100 disease-associated proteins; Polyploid; Pre-rRNA;
Protein complex; Proteome; PSMS; Psoriatics; Psoriasis; Pyrophosphatase; Quiescent; Rebinding; Regulatory; Repair; Reversible;
single MAGE-A antigen; Site-speciﬁc; Speciﬁc kinase-substrate; Squamous epithelium; Stimuli; Stratiﬁed; Stratiﬁed epithelia;
Subcellular; Subcomplex; Substrate; Subunit; Superfamilies; Suprabasal; Surface; Skin diseases; Starvation; Stratum corneum;
Synthesis; Temporal; Topologies; Transmission; Unaligned; Unattached; Viral protein; Xeroderma pigmentosum
Marmite Not mitosis-related: Psoriasis
FatiGO Mitosis-related: Chromosome, organization and biogenesis; DNA metabolic process; E2F; M phase of mitotic cell cycle; Cell cycle,
phase, process; Cell division; Chromosome segregation; DNA recombination, repair, replication; HNF1; Intermediate ﬁlament
cytoskeleton; MEF-2; Mitosis, cell cycle; Nucleobase, nucleoside, nucleotide and nucleic acid metabolic process; Rb:E2F-1:DP-1;
Response to DNA damage stimulus
Not mitosis-related: Anatomical structure development, morphogenesis; Apical junction complex; Apicolateral plasma membrane;
ATP binding; Biopolymer metabolic process; Cation binding; Cell adhesion, junction, part; Cellular component organization and
biogenesis, metabolic process; Corniﬁed envelope; Cytosol; Defense response; Ectoderm development; Epidermis development;
Extracellular region part, space; Integral to membrane, plasma membrane; Intercellular junction; Intracellular, membrane-bound
organelle; Intrinsic to membrane; Macromolecule metabolic process; Membrane-bound organelle; Multicellular organismal
development; Non-membrane-bound organelle; Nuclear part; Nucleic acid binding; Nucleotide binding; Nucleus; Organ
development; Organelle lumen; Plasma membrane; Primary metabolic process; Protein folding; Purine nucleotide binding;
Response to endogenous stimulus; RNA binding, localization, processing; System development; Tissue development
ProfCom —
In this table, diﬀerent tools have been used to compare a set of genes associated with primary melanoma, and a second set of genes associated with
metastatic melanoma. Each keyword or GO term found has been classiﬁed as either mitosis-related, uninformative, or ‘not mitosis-related’.
Compared with the other tools, Martini found more keywords, more-speciﬁc keywords, but also more uninformative keywords.
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forming tools reach only 60% recall (Table 3), indicating
that there is considerable scope for improving such tools.
For the benchmark, we also included CoPub, even
though this tool is not really similar to the others tested
here, since it cannot compare two gene lists. Given this,
CoPub performs rather well in the benchmark, with equal-
best recall. The lower precision (i.e. more false positives)
obtained by CoPub illustrates the beneﬁt of the two-set
approach.
Using the cell-cycle benchmark, Martini had markedly
better performance compared with the other tools we
tested (Table 3). In addition, assessed qualitatively,
Martini also had better or equal accuracy for each
of the other datasets presented here (Arabidopsis,
melanoma and ovarian cancer). Taken together, these
results suggest that Martini represents an advance in the
state-of-the-art in automated comparison of gene sets.
Once published, we await further feedback from end-
users applying Martini to wider range of cases to see if
this trend still holds.
Keywords versus GO terms
In our initial survey of tools for gene set analysis, we
found that almost all such tools rely on GO terms, often
exclusively (see ‘Introduction’ section), and only a small
number of methods used keywords. This suggests a per-
ception amongst many scientists in this ﬁeld that GO
terms are the preferred, more reliable source of functional
annotation for genes. Indeed, when we shared the results
presented here, many of our colleagues found it striking
that the GO-based tools (ProfCom and FatiGO)
performed in some cases much worse than a keyword-
based tool such as Martini.
Summarizing the performance of the tools with the
datasets we tested, we conclude that Martini performed
best, followed by FatiGO, then Marmite and ProfCom,
both performing similarly. Since FatiGO and ProfCom
are both GO-based, and since Martini and Marmite are
both based on similar keyword dictionaries, it is likely that
the poorer performance of Marmite and ProfCom arises
from the statistical methods used.
However, based on the performance diﬀerence between
Martini and FatiGO, plus the relatively good performance
of CoPub (Table 2), we conclude that keywords may be a
richer source of functional annotations than GO terms.
Since this runs contrary to the expectation of many
scientists in the ﬁeld, we decided to survey the density
of gene annotations from GO terms versus keywords.
As reported in the ‘Introduction’ section, in Entrez we
found that the median numbers of GO terms and
Medline citations per human gene are seven and nine,
respectively. Using the AKS2 keyword dictionary, we
get 32 keywords per abstract, and hence a median value
of over 100 unique keywords per gene. For well-studied
genes, the contrast between GO terms and keywords is
even stronger, e.g. the Entrez entry for human p53 has
74 GO terms compared with 2527 Medline abstracts,
which give rise to over 11000 unique keywords using
AKS2.
The appeal of GO terms likely derives from the use of a
controlled vocabulary, as well as the fact that annotation
of gene function using GO terms has been done rather
systematically. In contrast, extracting keywords automat-
ically from Medline abstracts could be expected to be
time-consuming, noisy and error-prone. However, both
Martini and CoPub demonstrate the feasibility of a
keyword-based approach. Furthermore, in agreement
with Ku ¨ ﬀner et al. (9), we ﬁnd that keywords appear to
give consistently better, and more speciﬁc results than GO
terms.
Tips for using Martini
In this section, we discuss some practical tips and issues
for end-users planning to use Martini to compare gene
sets.
First, we would advise end-users not to have too high
expectations when using any automated method to infer
function. Like all such methods, Martini does not always
produce good results. Martini depends entirely upon
the underlying literature associated with the genes in the
input sets: it may often occur that there is relatively little
literature, or that the literature does not adequately
describe the diﬀerences between the two genes sets. In
the results, we presented one such case—the ovarian
cancer dataset—where all of the tools tested produced
exactly zero results.
Secondly, our experience suggests that best results are
often obtained by asking very speciﬁc questions, i.e. by
comparing two closely related datasets. For example, in
Table 2 we used CoPub to compared four sets of  150
genes, on average, with the background of the remaining
 20000+ human genes; this produced good recall but
with many false positives, hence low precision. With
Martini, we got better results by asking a more speciﬁc
question, i.e. by comparing the  150 gene sets for each
cell-cycle phase against the remaining  450 genes
associated with the other phases (Table 2). In fact, as
can be seen by comparing the Martini keywords in
Table 2 with those in Figure 2, we got even better
results (many more keywords and more speciﬁc
keywords) with the same dataset, but asking an even
more speciﬁc question, e.g. comparing on average  60
genes in each 10% sub-region of the cell cycle to the
 540 genes in the remaining 90%.
Thirdly, in cases where only a single gene set is avail-
able, one strategy is to construct a second reference gene
set by randomly selecting a subset of genes from the same
organism. We suggest using a reference set that is several
times larger than the experimental set, and choosing genes
that each have greater than the median number of
abstracts for that species: for human, this means genes
with more than nine abstracts. We used a similar
strategy for the Arabidopsis dataset, and in this case it
produced good results. However, we stress again that
there can be no guarantee of producing informative
results with automated methods such as Martini.
Fourthly, an alternative strategy in the case of a single
experimental set is to use a tool such as Anni (3) or
TXTGate (2) that can interactively divide a single gene
36 Nucleic AcidsResearch, 2010,Vol. 38,No. 1set into functionally related sub-clusters. These sub-
clusters can then be compared using Martini.
Finally, to analyze the keywords produced by Martini,
we recommend the strategy adopted for the melanoma
dataset (Table 4) i.e. divide the keywords into three
groups:
(i) Keywords that are obvious, given the biological
context.
(ii) Keywords that are uninformative (e.g. keywords
such as ‘surprisingly’): Martini sometimes produces
many of these (e.g. Table 4), partly due to its large
keyword dictionary. Such generic keywords are
usually more annoying than troublesome, and we
plan to blacklist many of them in the future.
(iii) The remaining keywords are often the most
interesting, and are most likely to give novel
insight into the functional diﬀerences between the
two gene sets.
In some cases, Martini produces a list of keywords that
is very large. To help such cases, in the future, we plan that
the output list of keywords will be automatically
organized into similar biomedical concepts.
CONCLUSIONS
Martini is designed to be fast and easy-to-use, providing a
quick ﬁrst insight into the functional diﬀerence between
two gene sets. Our results suggest that Martini oﬀers a
signiﬁcant advance in the automated extraction of biolog-
ical knowledge from sets of genes or abstracts. Currently,
Martini focuses on ﬁnding diﬀerences between two
input sets; in the near future we plan to add an option
to search instead for commonalities between these sets, for
example to ﬁnd interactions involving genes from both
sets. In addition, we plan to improve Martini by adding
document classiﬁcation, by enabling the input of single
gene-lists, and by using sequence alignment tools to
extend functional annotation to similar sequences.
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